CN105441583A - 幽门螺杆菌多重基因检测体系及其试剂盒和应用 - Google Patents
幽门螺杆菌多重基因检测体系及其试剂盒和应用 Download PDFInfo
- Publication number
- CN105441583A CN105441583A CN201610070276.6A CN201610070276A CN105441583A CN 105441583 A CN105441583 A CN 105441583A CN 201610070276 A CN201610070276 A CN 201610070276A CN 105441583 A CN105441583 A CN 105441583A
- Authority
- CN
- China
- Prior art keywords
- gene
- seqidno
- nucleotide sequence
- primer
- vaca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 67
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 57
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 153
- 101150070420 gyrA gene Proteins 0.000 claims abstract description 30
- 101150039180 rdxA gene Proteins 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 101150014144 ureC gene Proteins 0.000 claims abstract description 23
- 101150114014 cagA gene Proteins 0.000 claims abstract description 21
- 101150078797 luxS gene Proteins 0.000 claims abstract description 21
- 101150073660 glmM gene Proteins 0.000 claims abstract description 15
- 230000001018 virulence Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims description 78
- 125000003729 nucleotide group Chemical group 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 21
- 239000013642 negative control Substances 0.000 claims description 10
- 239000013641 positive control Substances 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 108050009160 DNA polymerase 1 Proteins 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 21
- 206010059866 Drug resistance Diseases 0.000 abstract description 8
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 8
- 230000004907 flux Effects 0.000 abstract description 5
- 230000001360 synchronised effect Effects 0.000 abstract description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 abstract 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 abstract 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 abstract 1
- 238000011002 quantification Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000000523 sample Substances 0.000 description 22
- 238000005251 capillar electrophoresis Methods 0.000 description 19
- 239000012634 fragment Substances 0.000 description 15
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 11
- 229960002626 clarithromycin Drugs 0.000 description 11
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 10
- 229960003376 levofloxacin Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 9
- 229960000282 metronidazole Drugs 0.000 description 9
- 150000004684 trihydrates Chemical class 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- -1 Methane amide Chemical class 0.000 description 5
- 230000007923 virulence factor Effects 0.000 description 5
- 239000000304 virulence factor Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 101150080234 vacA gene Proteins 0.000 description 3
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070276.6A CN105441583B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌多重基因检测体系及其试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070276.6A CN105441583B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌多重基因检测体系及其试剂盒和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105441583A true CN105441583A (zh) | 2016-03-30 |
CN105441583B CN105441583B (zh) | 2019-02-26 |
Family
ID=55552205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610070276.6A Active CN105441583B (zh) | 2016-02-02 | 2016-02-02 | 幽门螺杆菌多重基因检测体系及其试剂盒和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105441583B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106086213A (zh) * | 2016-08-09 | 2016-11-09 | 新乡学院 | 口腔中幽门螺杆菌pcr检测方法 |
CN107037117A (zh) * | 2017-06-02 | 2017-08-11 | 华东医院 | 一种幽门螺杆菌的快速鉴定及毒力分析方法 |
CN107083446A (zh) * | 2017-06-27 | 2017-08-22 | 华东医院 | 腹泻病原菌多重基因检测体系及其试剂盒和应用 |
CN109182564A (zh) * | 2018-08-24 | 2019-01-11 | 上海芯超医学检验所有限公司 | 一种检测分析幽门螺旋杆菌的毒性及致病性的方法 |
CN109593842A (zh) * | 2018-12-21 | 2019-04-09 | 上海芯超医学检验所有限公司 | 一种检测和判定幽门螺旋杆菌耐药性的试剂盒和方法 |
CN109797203A (zh) * | 2019-01-24 | 2019-05-24 | 杭州和壹基因科技有限公司 | 幽门螺杆菌检测体系及检测试剂盒和应用 |
CN112342306A (zh) * | 2019-08-09 | 2021-02-09 | 沈阳祥伴科技有限公司 | 用于检测或辅助检测幽门螺杆菌的引物组合物以及试剂盒 |
CN111996273B (zh) * | 2020-11-02 | 2021-02-26 | 北京健为医学检验实验室有限公司 | 检测幽门螺杆菌耐药基因突变的方法及试剂盒 |
-
2016
- 2016-02-02 CN CN201610070276.6A patent/CN105441583B/zh active Active
Non-Patent Citations (6)
Title |
---|
周丽芳,等: "多重基因分析系统检测幽门螺杆菌的初步研究", 《检验医学》 * |
徐凯: "不同消化性疾病来源的幽门螺杆菌毒力基因cagA、vacA、oipA、dupA的检测及其意义", 《中国优秀硕士学位论文全文数据库(医药卫生科技辑)》 * |
施莉,等: "芯片检测幽门螺杆菌左氧氟沙星耐药gyrA基因突变的应用", 《中华检验医学杂志》 * |
李大欢,等: "贵州省某院幽门螺杆菌致病性的优势基因型特征", 《重庆医学》 * |
胡玢婕,等: "幽门螺杆菌生物膜形成与其耐药机制的相关性", 《检验医学》 * |
黄德强: "幽门螺杆菌耐药基因的 DNA 序列分析", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106086213A (zh) * | 2016-08-09 | 2016-11-09 | 新乡学院 | 口腔中幽门螺杆菌pcr检测方法 |
CN106086213B (zh) * | 2016-08-09 | 2020-02-25 | 新乡学院 | 口腔中幽门螺杆菌pcr检测方法 |
CN107037117A (zh) * | 2017-06-02 | 2017-08-11 | 华东医院 | 一种幽门螺杆菌的快速鉴定及毒力分析方法 |
CN107083446A (zh) * | 2017-06-27 | 2017-08-22 | 华东医院 | 腹泻病原菌多重基因检测体系及其试剂盒和应用 |
CN107083446B (zh) * | 2017-06-27 | 2021-03-16 | 华东医院 | 腹泻病原菌多重基因检测体系及其试剂盒和应用 |
CN109182564A (zh) * | 2018-08-24 | 2019-01-11 | 上海芯超医学检验所有限公司 | 一种检测分析幽门螺旋杆菌的毒性及致病性的方法 |
CN109593842A (zh) * | 2018-12-21 | 2019-04-09 | 上海芯超医学检验所有限公司 | 一种检测和判定幽门螺旋杆菌耐药性的试剂盒和方法 |
CN109593842B (zh) * | 2018-12-21 | 2021-01-01 | 上海芯超生物科技有限公司 | 一种检测和判定幽门螺旋杆菌耐药性的试剂盒和方法 |
CN109797203A (zh) * | 2019-01-24 | 2019-05-24 | 杭州和壹基因科技有限公司 | 幽门螺杆菌检测体系及检测试剂盒和应用 |
CN112342306A (zh) * | 2019-08-09 | 2021-02-09 | 沈阳祥伴科技有限公司 | 用于检测或辅助检测幽门螺杆菌的引物组合物以及试剂盒 |
CN111996273B (zh) * | 2020-11-02 | 2021-02-26 | 北京健为医学检验实验室有限公司 | 检测幽门螺杆菌耐药基因突变的方法及试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN105441583B (zh) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105441583A (zh) | 幽门螺杆菌多重基因检测体系及其试剂盒和应用 | |
AU2011227110B2 (en) | Methods, kits and compositions for detection of MRSA | |
Cerqueira et al. | PNA-FISH as a new diagnostic method for the determination of clarithromycin resistance of Helicobacter pylori | |
AU2013353904B2 (en) | Method for detecting Helicobacter pylori DNA in a stool sample | |
Herthnek et al. | New PCR systems to confirm real-time PCR detection of Mycobacterium avium subsp. paratuberculosis | |
CN103038348B (zh) | 通过使用双重实时聚合酶链式反应对结核分枝杆菌和非结核分枝杆菌进行检测的方法 | |
CN104745575A (zh) | 用于检测细胞增殖性异常或疾病程度分级的基因组合物及其用途 | |
Schmitt et al. | PCR detection of clarithromycin-susceptible and-resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies | |
Kargar et al. | Real-time PCR for Helicobacter pylori quantification and detection of clarithromycin resistance in gastric tissue from patients with gastrointestinal disorders | |
CN103397024B (zh) | 鸟分枝杆菌检测用引物和探针、以及使用它们检测鸟分枝杆菌的方法 | |
CN105506160A (zh) | 幽门螺杆菌定量和毒力多重基因检测体系及其试剂盒和应用 | |
CN105463124A (zh) | 幽门螺杆菌鉴定和毒力多重基因检测体系及其试剂盒和应用 | |
Debruyne et al. | Comparative performance of different PCR assays for the identification of Campylobacter jejuni and Campylobacter coli | |
JP2013504319A (ja) | ヘリコバクター・ピロリ及び/又はクラリスロマイシン抵抗性を検出するためのペプチド核酸プローブ、キット及び方法、及びその使用 | |
EP2341150A1 (en) | Breast cancer metastasis determination method and blood serum evaluation method | |
KR20110042511A (ko) | PNA 기반의 실시간 PCR 클램핑을 이용한 K-ras 돌연변이 검출 방법 및 키트 | |
CN105506161A (zh) | 幽门螺杆菌耐药和定量多重基因检测体系及其试剂盒和应用 | |
CN105441582A (zh) | 幽门螺杆菌定性和定量多重基因检测体系及其试剂盒和应用 | |
CN105368825A (zh) | 幽门螺杆菌抗生素耐药性分析试剂盒及耐药性检测方法 | |
CN109929931A (zh) | 一种胃癌风险基因检测的试剂盒及其使用方法 | |
CN103224932A (zh) | 胞内分枝杆菌检测用引物和探针、以及使用该引物和探针检测胞内分枝杆菌的方法 | |
MX2015003386A (es) | Metodo para la deteccion de mutaciones de braf y pi3k. | |
FI126289B (en) | Method for detecting the presence of a hypervirulent Clostridium difficile strain | |
Erill et al. | A novel multiplexing, polymerase chain reaction-based assay for the analysis of chromosome 18q status in colorectal cancer | |
CN118006815A (zh) | 具核梭杆菌特异性dna序列及其应用和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180605 Address after: 200040 West Yan'an Road, Jingan District, Shanghai, No. 221 Applicant after: HUADONG Hospital Applicant after: Ningbo Health Gene Technologies Co.,Ltd. Address before: 200040 West Yan'an Road, Jingan District, Shanghai, No. 221 Applicant before: Huadong Hospital |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 200040 No. 221, Jingan District, Shanghai, West Yan'an Road Patentee after: HUADONG Hospital Country or region after: China Patentee after: Ningbo Haier Shi Gene Technology Co.,Ltd. Address before: 200040 No. 221, Jingan District, Shanghai, West Yan'an Road Patentee before: HUADONG Hospital Country or region before: China Patentee before: Ningbo Health Gene Technologies Co.,Ltd. |